COMT polymorphism and the risk of endometriosis-related infertility

Gynecological Endocrinology

Volumn 27, Issue 12, 2011, Pages 1099-1102

  Christofolini, Denise Maria ^a   Teles, Juliana Souto ^a   Vilarino, Fábia Lima ^a   André, Gustavo Mendonça ^a   Bianco, Bianca ^a   Barbosa, Caio Parente ^a  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

Author keywords

COMT; Endometriosis; estrogen hormone; infertility; polymorphism

Indexed keywords

CATECHOL METHYLTRANSFERASE; ESTROGEN;

ADULT; ARTICLE; CONTROLLED STUDY; ENDOMETRIOSIS; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; INFERTILITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; BRAZIL; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; ENDOMETRIOSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFERTILITY, FEMALE; LINKAGE DISEQUILIBRIUM; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UTERINE DISEASES;

EID: 80054721528     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.569797     Document Type: Article

References (26)

1. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364: 1789-1799.
2. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue to the peritoneal cavity. Am J Obstet Gynecol 1927;14:422-469.
3. Matarese G, De Placido G, Nikas Y, Alviggi C. Pathogenesis of endometriosis: natural immunity dysfunction or autoimmune disease? Trends Mol Med 2003;9:223-228.
4. Wells M. Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation. Int J Gynecol Pathol 2004;23:316-320.
5. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998;58:2269-2277.
6. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-433.
7. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-4791.
8. Bolton JL, Thatcher GR. Potential mechanisms of estrogen quinone carcinogenesis. Chem Res Toxicol 2008;21:93-101.
9. Hevir N, Sinkovec J, Riẑer TL. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of SCOMT. Mol Cell Endocrinol 2011;331:158-167.
10. Cavalieri E, Rogan E. Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann NY Acad Sci 2006;1089:286-301.
11. Delort L, Satih S, Kwiatkowski F, Bignon YJ, Bernard- Gallon DJ. Evaluation of breast cancer risk in a multigenic model including low penetrance genes involved in xenobiotic and estrogen metabolisms. Nutr Cancer 2010;62:243-251.
12. Revised American Society for Reproductive Medicine classification of endometriosis. Fertil Steril 1997;67:817-821.
13. Lahiri DK, Numberger JI. A rapid non-enzymatic method for preparation of HMW DNA from blood for RFLP studies. Nuclei Acids Res 1991;19:5444.
14. Somigliana E, Vigano P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecologic oncology 2006;101:331-341.
15. Mandai M, Yamaguchi K, Matsumura N, Baba T, Konishi I. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 2009;14:383-391.
16. Joosten HF, van Acker FA, van den Dobbelsteen DJ, Horbach GJ, Krajnc EI. Genotoxicity of hormonal steroids. Toxicol Lett 2004;151:113-134.
17. Weisz J, Clawson GA, Creveling CR. Biogenesis and inactivation of catecholestrogens. Adv Pharmacol 1998;42: 828-833.
18. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransfse pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-250.
19. Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransfse, thiopurine methyltransfse, and histamine N-methyltransfse. Annu Rev Pharmacol Toxicol 1999;39:19-52.
20. Huber JC, Schneeberger C, Tempfer CB. Genetic modeling of the estrogen metabolism as a risk factor of hormonedependent disorders. Maturitas 2002;42:1-12.
21. Wieser F, Wenzl R, Tempfer C, Worda C, Huber J, Schneeberger C. Catechol-O-methyltransfse polymorphism and endometriosis. J Assist Reprod Genet 2002;19: 343-348.
22. Juo SH, Wang TN, Lee JN, Wu MT, Long CY, Tsai EM. CYP17, CYP1A1 and COMT polymorphisms and the risk of adenomyosis and endometriosis in Taiwanese women. Hum Reprod 2006;21:1498-1502.
23. Barbosa CP, Souza AM, Bianco B, Christofolini D, Bach FA, Lima GR. Frequency of endometriotic lesions in peritoneum samples from asymptomatic fertile women and correlation with CA125 values. Sao Paulo Med J 2009;127: 342-345.
24. Montgomery GW, Nyholt DR, Zhao ZZ, Treloar SA, Painter JN, Missmer SA, Kennedy SH, Zondervan KT. The search for genes contributing to endometriosis risk. Hum Reprod Update 2008;14:447-457.
25. Gan XL, Lin YH, Zhang Y, Yu TH, Hu LN. Association of an interleukin-16 gene polymorphism with the risk and pain phenotype of endometriosis. DNA Cell Biol 2010;29: 663-667.
26. Zhao ZZ, Croft L, Nyholt DR, Chapman B, Treloar SA, Hull ML, Montgomery GW. Evaluation of polymorphisms in predicted target sites for micro RNAs differentially expressed in endometriosis. Mol Hum Reprod 2011;17:92-103.